Bisoprolol
- Generic Name
- Bisoprolol
- Brand Names
- Ziac
- Drug Type
- Small Molecule
- Chemical Formula
- C18H31NO4
- CAS Number
- 66722-44-9
- Unique Ingredient Identifier
- Y41JS2NL6U
- Background
Bisoprolol is a cardioselective β1-adrenergic blocking agent used to treat high blood pressure. It is considered a potent drug with a long-half life that can be used once daily to reduce the need for multiple doses of antihypertensive drugs. Bisoprolol is generally well tolerated, likely due to its β1-adrenergic receptor selectivity and is a useful alternati...
- Indication
Bisoprolol is indicated for the treatment of mild to moderate hypertension. It may be used off-label to treat heart failure, atrial fibrillation, and angina pectoris.
- Associated Conditions
- Atrial Fibrillation, Cardiovascular Events, Chronic Stable Angina Pectoris, Heart Failure, Hypertension, Mild Hypertension, Premature Ventricular Contraction (PVC), Supraventricular Arrhythmias, Moderate Hypertension, Perioperative arrhythmia
- Associated Therapies
- -
Bisoprolol Versus Corticosteroid and Bisoprolol Combination for Prophylaxis Against Atrial Fibrillation After on Pump Coronary Artery Bypass Surgery
- First Posted Date
- 2019-01-11
- Last Posted Date
- 2019-01-15
- Lead Sponsor
- Ain Shams University
- Target Recruit Count
- 176
- Registration Number
- NCT03800264
- Locations
- 🇪🇬
Ramymahrose, Cairo, Egypt
Danish Trial of Beta Blocker Treatment After Myocardial Infarction Without Reduced Ejection Fraction
- Conditions
- Interventions
- First Posted Date
- 2018-12-19
- Last Posted Date
- 2024-12-11
- Lead Sponsor
- Bispebjerg Hospital
- Target Recruit Count
- 2760
- Registration Number
- NCT03778554
- Locations
- 🇩🇰
Bispebjerg Hospital, Dept. of Cardiology Y builing 67, 1.floor, Bispebjerg Bakke 23, Copenhagen, Denmark
Bisoprolol in DMD Early Cardiomyopathy
- Conditions
- Interventions
- First Posted Date
- 2018-12-19
- Last Posted Date
- 2022-09-28
- Lead Sponsor
- Peking Union Medical College Hospital
- Target Recruit Count
- 42
- Registration Number
- NCT03779646
- Locations
- 🇨🇳
Peking Union Medical College Hospital, Beijing, Beijing, China
Early Use of Ivabradine in Heart Failure
- Conditions
- Interventions
- First Posted Date
- 2018-10-10
- Last Posted Date
- 2018-10-11
- Lead Sponsor
- Ain Shams University
- Target Recruit Count
- 50
- Registration Number
- NCT03701880
- Locations
- 🇪🇬
El Demerdash Hospital, Cairo, Egypt
Pharmacokinetic Drug-Drug Interaction Between Bisoprolol and Ivabradine in Healthy Volunteers
- Conditions
- Interventions
- First Posted Date
- 2018-04-02
- Last Posted Date
- 2018-04-02
- Lead Sponsor
- Ain Shams University
- Target Recruit Count
- 18
- Registration Number
- NCT03485482
- Locations
- 🇪🇬
Faculty of Pharmacy, Cairo, Egypt
Evaluation of Decreased Usage of Betablockers After Myocardial Infarction in the SWEDEHEART Registry (REDUCE-SWEDEHEART)
- Conditions
- Interventions
- First Posted Date
- 2017-09-11
- Last Posted Date
- 2024-03-05
- Lead Sponsor
- Karolinska Institutet
- Target Recruit Count
- 5000
- Registration Number
- NCT03278509
- Locations
- 🇸🇪
Danderyd Hospital, Cardiac Intensive Care, Danderyd, Stockholms Län, Sweden
A Study on Molecular Genetics of Drug Responsiveness in Essential Hypertension
- Conditions
- Interventions
- First Posted Date
- 2017-09-08
- Last Posted Date
- 2017-09-11
- Lead Sponsor
- Helsinki University Central Hospital
- Target Recruit Count
- 233
- Registration Number
- NCT03276598
- Locations
- 🇫🇮
Helsinki University Central Hospital, Helsinki, Finland
Bioequivalence Trial of Concor AM® vs Bisoprolol and Amlodipine in Chinese Participants
- Conditions
- Interventions
- First Posted Date
- 2017-07-21
- Last Posted Date
- 2019-02-20
- Lead Sponsor
- Merck KGaA, Darmstadt, Germany
- Target Recruit Count
- 32
- Registration Number
- NCT03226275
- Locations
- 🇨🇳
Xuanwu Hospital, Beijing, China
Efficacy of Oral Bisoprolol on Heart Rate Reduction in Chinese Chronic Heart Failure Participants
- First Posted Date
- 2017-01-20
- Last Posted Date
- 2020-01-29
- Lead Sponsor
- Merck KGaA, Darmstadt, Germany
- Target Recruit Count
- 20
- Registration Number
- NCT03026088
- Locations
- 🇨🇳
Fuwai Hospital Chinese Academy of Medical Sciences, Beijing, China
Sequential Nephron Blockade vs. Dual Blockade Renin-angiotensin System + Bisoprolol in Resistant Arterial Hypertension
- Conditions
- Interventions
- First Posted Date
- 2016-07-14
- Last Posted Date
- 2019-04-05
- Lead Sponsor
- Sao Jose do Rio Preto Medical School
- Target Recruit Count
- 72
- Registration Number
- NCT02832973
- Locations
- 🇧🇷
Juan Carlos Yugar-Toledo, São José do Rio Preto, São Paulo, Brazil
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.